Suppr超能文献

内皮抑素的基因转移增强了阿霉素抑制小鼠人肝细胞癌的疗效。

Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice.

作者信息

Liu Fengjun, Tan Gang, Li Jie, Dong Xuesong, Krissansen Geoffrey W, Sun Xueying

机构信息

Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China.

出版信息

Cancer Sci. 2007 Sep;98(9):1381-7. doi: 10.1111/j.1349-7006.2007.00542.x. Epub 2007 Jul 11.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death, and is chemoresistant to anticancer drugs. Anti-angiogenic therapy has been shown to enhance the efficacy of chemotherapy to treat solid tumors. The aim of the present study was to determine whether endostatin, a potent antiangiogenic agent, could enhance the efficacy of doxorubicin to combat HCC. An endostatin expression plasmid was constructed and its expression in vitro and in vivo was detected after gene transfer. Recombinant endostatin inhibited angiogenesis in the chorioallantoic membrane assay, and showed synergistic effects with doxorubicin in inhibiting the in vitro proliferation of endothelial cells, but not that of tumor cells. Both endostatin gene therapy and doxorubicin suppressed the growth of subcutaneous human HepG2 tumors established in BALB/c nude mice, and tumor angiogenesis. Combination therapy with endostatin gene therapy and doxorubicin showed a stronger effect in suppressing tumor growth, and tumor angiogenesis, than the respective monotherapies. Gene transfer of endostatin down-regulated the expression of both hypoxia-inducible factor-1alpha and vascular endothelial growth factor (VEGF), whereas doxorubicin only down-regulated VEGF expression. Endostatin and doxorubicin synergized to down-regulate VEGF expression. Endostatin and doxorubicin combination therapy warrants investigation as a therapeutic strategy to combat HCC.

摘要

肝细胞癌(HCC)是癌症相关最常见的死亡原因之一,并且对抗癌药物具有化学抗性。抗血管生成疗法已被证明可增强化疗治疗实体瘤的疗效。本研究的目的是确定强效抗血管生成剂内皮抑素是否能增强阿霉素对抗HCC的疗效。构建了内皮抑素表达质粒,并在基因转移后检测其在体内外的表达。重组内皮抑素在鸡胚绒毛尿囊膜试验中抑制血管生成,并在抑制内皮细胞而非肿瘤细胞的体外增殖方面与阿霉素显示出协同作用。内皮抑素基因治疗和阿霉素均抑制了在BALB/c裸鼠中建立的皮下人HepG2肿瘤的生长以及肿瘤血管生成。内皮抑素基因治疗与阿霉素联合治疗在抑制肿瘤生长和肿瘤血管生成方面比各自的单一疗法显示出更强的效果。内皮抑素的基因转移下调了缺氧诱导因子-1α和血管内皮生长因子(VEGF)的表达,而阿霉素仅下调VEGF的表达。内皮抑素和阿霉素协同下调VEGF表达。内皮抑素与阿霉素联合治疗作为对抗HCC的治疗策略值得研究。

相似文献

1
Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice.
Cancer Sci. 2007 Sep;98(9):1381-7. doi: 10.1111/j.1349-7006.2007.00542.x. Epub 2007 Jul 11.
4
Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.
J Biomed Sci. 2008 Jan;15(1):99-109. doi: 10.1007/s11373-007-9201-3. Epub 2007 Aug 18.
6
Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice.
Cancer Biol Ther. 2009 Mar;8(5):466-73. doi: 10.4161/cbt.8.5.7687. Epub 2009 Mar 21.
7
Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery.
World J Gastroenterol. 2004 Jul 1;10(13):1867-71. doi: 10.3748/wjg.v10.i13.1867.
8
Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.
BMC Cancer. 2017 Dec 28;17(1):899. doi: 10.1186/s12885-017-3903-3.
9
Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth.
Cancer Lett. 2011 Feb 28;301(2):212-20. doi: 10.1016/j.canlet.2010.12.004. Epub 2011 Jan 7.

引用本文的文献

2
A self-guidance biological hybrid drug delivery system driven by anaerobes to inhibit the proliferation and metastasis of colon cancer.
Asian J Pharm Sci. 2022 Nov;17(6):892-907. doi: 10.1016/j.ajps.2022.09.003. Epub 2022 Oct 19.
3
Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma.
Int J Mol Sci. 2018 Oct 8;19(10):3070. doi: 10.3390/ijms19103070.
5
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.
Pharmaceuticals (Basel). 2010 Mar 8;3(3):482-513. doi: 10.3390/ph3030482.
6
Effects of the C-terminal of endostatin on the tumorigenic potential of H22 cells.
Biomed Rep. 2013 Sep;1(5):761-765. doi: 10.3892/br.2013.147. Epub 2013 Jul 22.
8
Delivery of the co-expression plasmid pEndo-Si-Stat3 by attenuated Salmonella serovar typhimurium for prostate cancer treatment.
J Cancer Res Clin Oncol. 2013 Jun;139(6):971-80. doi: 10.1007/s00432-013-1398-0. Epub 2013 Mar 5.
9
Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
PLoS One. 2012;7(8):e42921. doi: 10.1371/journal.pone.0042921. Epub 2012 Aug 10.

本文引用的文献

1
Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas.
Dig Liver Dis. 2007 Jun;39(6):557-65. doi: 10.1016/j.dld.2007.01.025. Epub 2007 Mar 19.
2
Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy.
J Hepatol. 2007 Jan;46(1):98-106. doi: 10.1016/j.jhep.2006.07.031. Epub 2006 Sep 25.
3
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
Oncologist. 2006 Jul-Aug;11(7):790-800. doi: 10.1634/theoncologist.11-7-790.
5
Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Exp Cell Res. 2006 Mar 10;312(5):594-607. doi: 10.1016/j.yexcr.2005.11.015. Epub 2005 Dec 22.
7
8
Endostatin: the logic of antiangiogenic therapy.
Drug Resist Updat. 2005 Feb-Apr;8(1-2):59-74. doi: 10.1016/j.drup.2005.03.001. Epub 2005 Apr 7.
9
Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine.
Anticancer Drugs. 2005 Jun;16(5):551-7. doi: 10.1097/00001813-200506000-00011.
10
Global cancer statistics, 2002.
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验